<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280056</url>
  </required_header>
  <id_info>
    <org_study_id>BCT-002-US</org_study_id>
    <nct_id>NCT03280056</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients</brief_title>
  <official_title>A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainstorm-Cell Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brainstorm-Cell Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of repeated administration of NurOwn®&#xD;
      (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived&#xD;
      mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow,&#xD;
      propagated ex vivo and induced to secrete Neurotrophic factors (NTFs).&#xD;
&#xD;
      The autologous NurOwn® (MSC-NTF cells) are back-transplanted into the patient intrathecally&#xD;
      by standard lumbar puncture where neurons and glial cells are expected to take up the&#xD;
      neurotrophic factors secreted by the transplanted cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurotrophic factors (NTFs) are potent survival factors for embryonic, neonatal, and adult&#xD;
      neurons and are considered potential therapeutic candidates for ALS. Delivery of multiple&#xD;
      NTFs to the immediate environment of afflicted neurons in ALS patients is expected to improve&#xD;
      their survival and thus slow down disease progression and alleviate symptoms. NTF-secreting&#xD;
      mesenchymal stromal cells (MSC-NTF cells) are a novel cell-therapeutic approach aimed at&#xD;
      effectively delivering NTFs directly to the site of damage in ALS patients.&#xD;
&#xD;
      Participants meeting the inclusion and exclusion criteria will be randomized and will undergo&#xD;
      bone-marrow aspiration. MSC of the participants randomized to the treatment group will be&#xD;
      induced into MSC-NTF cells. Participants will undergo a total of three intrathecal (IT)&#xD;
      transplantations with NurOwn® (MSC-NTF cells) or matching placebo at three bi-monthly&#xD;
      intervals&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled Multicenter Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double-blind study where the investigators, participants and all sponsor and CRO personnel involved in the conduct, data management or analysis of the study will remain blinded to the treatment assignments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)</measure>
    <time_frame>28 weeks following the first treatment</time_frame>
    <description>To determine efficacy and safety of repeat intrathecal injections of NurOwn® as compared to Placebo given three times two months apart to participants with Amyotrophic Lateral Sclerosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Through selected post-treatment time points up to 20 weeks post transplant</time_frame>
    <description>To evaluate biomarkers (such as cell-secreted neurothrophic factors, inflammatory factors, and cytokines in pg/ml) in the cerebrospinal fluid (CSF) as well as in serum samples throughout the study to evaluate their relationship to treatment with NurOwn® (MSC-NTF cells)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>NurOwn® (MSC-NTF cells)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three Intrathecal administrations of Placebo at bi-monthly intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NurOwn® (MSC-NTF cells)</intervention_name>
    <description>Autologous transplantation of bone marrow derived mesenchymal stem cells propagated ex vivo and induced to secrete neurotrophic factors</description>
    <arm_group_label>NurOwn® (MSC-NTF cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone Marrow aspiration</intervention_name>
    <description>Bone Marrow aspiration</description>
    <arm_group_label>NurOwn® (MSC-NTF cells)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALS diagnosed as possible, laboratory-supported probable, probable, or definite as&#xD;
             defined by revised El Escorial criteria.&#xD;
&#xD;
          -  Having onset of ALS disease symptoms, including limb weakness within 24 months at the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  ALSFRS-R ≥ 25 at the screening Visit.&#xD;
&#xD;
          -  Upright slow vital capacity (SVC) measure ≥ 65% of predicted for gender, height, and&#xD;
             age at the screening Visit.&#xD;
&#xD;
          -  Rapid progressors&#xD;
&#xD;
          -  Participants taking a stable dose of Riluzole are permitted in the study&#xD;
&#xD;
          -  Citizen or permanent resident of the United States or Canadian citizen able to travel&#xD;
             to a US site for all follow-up study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior stem cell therapy of any kind&#xD;
&#xD;
          -  History of autoimmune or other serious disease (including malignancy and immune&#xD;
             deficiency) that may confound study results&#xD;
&#xD;
          -  Current use of immunosuppressant medication or anticoagulants (per Investigator&#xD;
             discretion)&#xD;
&#xD;
          -  Exposure to any other experimental agent or participation in an ALS clinical trial&#xD;
             within 30 days prior to Screening Visit&#xD;
&#xD;
          -  Use of RADICAVA (edaravone injection) within 30 days of screening or intent to use&#xD;
             edaravone at any time during the course of the study including the follow up period&#xD;
&#xD;
          -  Use of non-invasive ventilation (BIPAP), diaphragm pacing system or invasive&#xD;
             ventilation (tracheostomy)&#xD;
&#xD;
          -  Feeding tube&#xD;
&#xD;
          -  Pregnant women or women currently breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit E. Cudkowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert H. Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony J. Windebank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Namita A. Goyal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert G. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center (CPM) Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Baloh, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine Alpha Stem Cell Clinic</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <disposition_first_submitted>October 3, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>October 3, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 5, 2021</disposition_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSC</keyword>
  <keyword>Autologous</keyword>
  <keyword>Neurotrophic factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

